Brentuximab Vedotin (SGN-35) in a 3-Year-Old Child With Relapsed Systemic Anaplastic Large Cell Lymphoma

Mikles, Bethany; Levine, Jennifer; Gindin, Tatyana; Bhagat, Govind; Satwani, Prakash

doi:10.1097/mph.0b013e31828aff2c

Cited by 11 publications

(8 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As it was previously published, retreatment with BV can induce repeated complete remission in relapsed systemic ALCL when considering combining BV with other therapeutic options [16]. Lower dose of BV (1 mg/kg) also showed its efficiency in a young child treatment with refractory ALCL, minimizing toxic effects [13]. Our patient received BV at a dose of 1.8 mg/kg before alloHSCT, which was allowed to perform transplantation during molecular remission, and at a dose of 1.2 mg/kg after alloHSCT, which was adequate to induce molecular and sustain clinical response.…”

Section: Discussionmentioning

confidence: 72%

Brentuximab Vedotin Monotherapy and Combined with Low Dose Donor Lymphocyte Infusion to Control Minimal Residual Disease and Sustain Clinical Remission in a Child with Relapsed Anaplastic Large Cell Lymphoma

Fedorova¹,

Stegantseva²,

Minakovskaya³

et al. 2017

JCT

View full text Add to dashboard Cite

Minimal residual disease (MRD) appears to have a strong negative predictive value for disease recurrence in children with anaplastic large cell lymphoma (ALCL). Brentuximab vedotin (BV) can be a therapeutic option for MRDpositive patients to achieve molecular remission and to decrease risk of subsequent relapse. We here report a 4-year-old child with ALCL progression during relapse treatment who received BV as a bridging therapy before haploidentical hematopoietic stem-cell transplantation, and as a maintenance therapy post-transplant alone or combined with simultaneous low dose donor-lymphocyte infusions. MRD monitoring showed a complete molecular response and reflected both BV efficiency and graft-versus-lymphoma effect.

show abstract

Section: Discussionmentioning

confidence: 72%

Brentuximab Vedotin Monotherapy and Combined with Low Dose Donor Lymphocyte Infusion to Control Minimal Residual Disease and Sustain Clinical Remission in a Child with Relapsed Anaplastic Large Cell Lymphoma

Fedorova¹,

Stegantseva²,

Minakovskaya³

et al. 2017

JCT

View full text Add to dashboard Cite

show abstract

“…Recently, targeted drugs such as brentuximab vedotin or ALK inhibitors have been developed and have yielded remarkable response rates with limited toxicities. 29,30,[33][34][35][36] However, the follow-up of the patients treated with these new targeted therapies is still short and we still do not know whether they will be able to lead to complete cure of ALCL or if they will have to be considered as a bridge to induce complete response before allo-SCT.…”

Section: Discussionmentioning

confidence: 99%

Hematopoietic stem cell transplantation in relapsed ALK+ anaplastic large cell lymphoma in children and adolescents: a study on behalf of the SFCE and SFGM-TC

Strullu

Thomas

Deley

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a treatment option for relapsed anaplastic large cell lymphoma (ALCL) in children, but reports on its efficacy in this disease are still limited. We analyzed data concerning 34 patients under 18 years of age prospectively registered in the French SFGM-TC database, who had undergone an allo-SCT for the treatment of ALK+ ALCL between 1993 and 2011. At transplant, 28 patients (82.4%) were in CR, whereas 6 exhibited detectable disease. Conditioning regimens were mostly myelo-ablative (n = 31). With a median follow-up of 6 years, 5-year overall and event-free survival rates were 70% (SE = 8%) and 58% (SE = 9%), respectively. The 5-year cumulative incidence of relapse and treatment-related mortality was 18% (SE = 7%) and 24% (SE = 8%), respectively. Six patients had relapsed (median time, 141 days (35-235)). A durable CR had been obtained in 4/6 patients after injection of donor lymphocytes (n = 1) or vinblastine-corticosteroid therapy (n = 3). Ten patients had died, eight due to transplant toxicity and two due to progressive disease. Allo-SCT is an efficient treatment for pediatric patients with high-risk relapsed ALK+ ALCL. However, the overall morbidity of allo-SCT raises questions about its place, given the efficacy of targeted agents currently under development in this disease. 1 Treatments based on multiagent chemotherapy over a short period (o 6 months) are successful in most patients. Bone Marrow Transplantation2 However, relapses occur in 25-30% of cases, mostly within 6 months after treatment.3 CR can once again be achieved at relapse in most patients with a wide variety of chemotherapy regimens. Thus, the 2-year overall survival rate in children treated for an ALCL exceeds 85% in the most recent reports and has attained 94% in the ALCL99 international trial.2 In most patients, the treatment strategy for relapse comprises autologous or allogeneic hematopoietic stem cell transplantation (allo-SCT) after a CR. The feasibility and efficacy of allo-SCT with good engraftment, acceptable toxicity and event-free survival rate ranging from 45 to 75% has been demonstrated in small series and case reports published so far.

show abstract

“…The initial experience with BV is limited to case reports of pediatric patients with (r/r) HL or ALCL [ 34 ]. Safety of BV was confirmed in a phase I/II study of pediatric patients with (r/r) lymphomas and maximum tolerated dose was found to be 1.8 mg/kg every three weeks [ 35 ].…”

Section: Antibody-drug Conjugates (Adc)mentioning

confidence: 99%

Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future

Sorge¹,

McDaniel²,

Xavier³

2016

Pharmaceuticals

View full text Add to dashboard Cite

Pediatric Non-Hodgkin Lymphomas (NHL) are a diverse group of malignancies and as such treatment can vary based on the different biological characteristics of each malignancy. Significant advancements are being made in the treatment and outcomes of this group of malignancies. This is in large part due to novel targeted drug therapies that are being used in combination with traditional chemotherapy. Here, we discuss several new lines of therapy that are being developed or are in current use for pediatric patients with NHL.

show abstract

Brentuximab Vedotin (SGN-35) in a 3-Year-Old Child With Relapsed Systemic Anaplastic Large Cell Lymphoma

Cited by 11 publications

References 1 publication

Brentuximab Vedotin Monotherapy and Combined with Low Dose Donor Lymphocyte Infusion to Control Minimal Residual Disease and Sustain Clinical Remission in a Child with Relapsed Anaplastic Large Cell Lymphoma

Brentuximab Vedotin Monotherapy and Combined with Low Dose Donor Lymphocyte Infusion to Control Minimal Residual Disease and Sustain Clinical Remission in a Child with Relapsed Anaplastic Large Cell Lymphoma

Hematopoietic stem cell transplantation in relapsed ALK+ anaplastic large cell lymphoma in children and adolescents: a study on behalf of the SFCE and SFGM-TC

Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future

Contact Info

Product

Resources

About